EOS Connection 2021 will feature the latest research developments, practical management strategies, and opportunities for attendees to connect on an all-virtual platform
(Atlanta, GA)—The American Partnership for Eosinophilic Disorders (APFED) will host its 19th annual patient education conference, which features a three-day virtual program on eosinophil-associated diseases.
EOS Connection 2021 will provide a full conference experience using state-of-the-art virtual meeting technology. Patients, caregivers, families, advocates, healthcare providers, researchers, and education partners can learn and connect in the online environment that includes a theater to watch presentations, a poster hall highlighting new research, a networking lounge where attendees can interact, a new chat feature via text or video, and an exhibit hall where attendees can interact with conference partners, access resources and learn about products, services, and enrolling clinical trials.
Eosinophil-associated diseases are chronic inflammatory conditions characterized by elevated levels of eosinophils (a type of white blood cell) in one or more specific areas of the body. The higher-than-normal number of eosinophils cause inflammation and damage to tissues and organs. These chronic diseases require lifelong treatment and symptoms may be debilitating.
The live virtual events for EOS Connection 2021 will take place July 14- 16 from 11:30 a.m. to 3:45 p.m. Eastern Time each day. Presentations from expert speakers will include sessions on research advancements in eosinophilic gastrointestinal diseases and dietary therapies, as well as presentations specific to other subsets of eosinophil-associated diseases, including but not limited to eosinophilic asthma. Attendees will also have opportunities to participate in live Q&A with the majority of presenters. After the live events conclude, recordings of the presentations and the poster and exhibit halls will continue to be available to attendees for on-demand access.
“This year’s agenda addresses a broad range of topics of importance to the eosinophilic disease community, and we’re grateful to our presenters, partners, and collaborators at CEGIR for the opportunity to deliver such an innovative and dynamic virtual education experience,” said APFED’s Executive Director Mary Jo Strobel. “We are pleased that the virtual format allows EOS Connection to once again widen our audience and become a true global event.”
Complimentary admission to EOS Connection 2021 is available to all APFED members.
EOS Connection 2021 is made possible thanks to the generous support of APFED’s Education Partners, including Presenting Partner Takeda; Diamond Partner Sanofi Genzyme and Regeneron; Platinum Partners Allakos, AstraZeneca, Abbott, Ellodi Pharmaceuticals, and Mead Johnson Nutrition; and Gold Partners Bristol Myers Squibb, GlaxoSmithKline, Nutricia Neocate®, and Revolo Biotherapeutics.
To register for EOS Connection 2021, please visit: apfed.org/conference.
About the American Partnership for Eosinophilic Disorders (APFED)
The American Partnership for Eosinophilic Disorders (APFED) is a non-profit organization whose mission is to passionately embrace, support, and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research, support, and advocacy. https://apfed.org/